Travere Therapeutics, Inc.
TVTX
$28.27
$0.471.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.73M | 25.71M | -12.76M | -41.23M | -60.26M |
| Total Depreciation and Amortization | 18.14M | 15.79M | 14.02M | 12.80M | 12.09M |
| Total Amortization of Deferred Charges | 1.64M | -- | -- | -- | 1.73M |
| Total Other Non-Cash Items | -14.49M | 10.16M | 9.36M | 9.92M | 3.33M |
| Change in Net Operating Assets | 52.67M | -37.33M | -5.64M | -23.69M | 7.40M |
| Cash from Operations | 60.68M | 14.32M | 4.98M | -42.19M | -35.72M |
| Capital Expenditure | 375.00K | -140.00K | -235.00K | -- | 82.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -105.21M | 86.73M | 5.09M | 41.29M | -80.39M |
| Cash from Investing | -104.84M | 86.59M | 4.85M | 41.29M | -80.31M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -68.90M | -- | -- | -- |
| Issuance of Common Stock | 27.20M | 4.09M | 2.00M | 4.24M | 139.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -525.00K | -525.00K | -525.00K | -525.00K | -525.00K |
| Cash from Financing | 26.68M | -65.34M | 1.48M | 3.72M | 139.12M |
| Foreign Exchange rate Adjustments | -413.00K | 207.00K | 1.95M | 548.00K | -964.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.90M | 35.78M | 13.26M | 3.36M | 22.13M |